Working with TipRanks
Follow Us
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Brainstorm Cell Therapeutics (BCLI)
NASDAQ:BCLI
RESEARCH TOOLSreports
Brainstorm Cell Therapeutics (BCLI) Stock Price & Analysis
422 Followers
BCLI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.14 - $3.72
Previous Close$0.18
Volume1.50M
Average Volume (3M)1.65M
Market Cap
$8.10M
Enterprise Value$10.65M
Total Cash (Recent Filing)$748.00K
Total Debt (Recent Filing)$3.29M
Price to Earnings (P/E)-0.3
Beta0.83
Next Earnings
Nov 13, 2023EPS Estimate
-$0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.60
Shares Outstanding45,015,800
10 Day Avg. Volume6,789,606
30 Day Avg. Volume1,647,942
Standard Deviation0.26
R-Squared0.00215
Alpha-0.00025
Financial Highlights & Ratios
Price to Book (P/B)-1.97
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.48
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Brainstorm Cell Therapeutics News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BCLI FAQ
What was Brainstorm Cell Therapeutics’s price range in the past 12 months?
Brainstorm Cell Therapeutics lowest stock price was $0.14 and its highest was $3.72 in the past 12 months.
What is Brainstorm Cell Therapeutics’s market cap?
Currently, no data Available
When is Brainstorm Cell Therapeutics’s upcoming earnings report date?
Brainstorm Cell Therapeutics’s upcoming earnings report date is Nov 13, 2023 which is in 26 days.
How were Brainstorm Cell Therapeutics’s earnings last quarter?
Brainstorm Cell Therapeutics released its earnings results on Aug 14, 2023. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.145 by $0.015.
Is Brainstorm Cell Therapeutics overvalued?
According to Wall Street analysts Brainstorm Cell Therapeutics’s price is currently Overvalued.
Does Brainstorm Cell Therapeutics pay dividends?
Brainstorm Cell Therapeutics does not currently pay dividends.
What is Brainstorm Cell Therapeutics’s EPS estimate?
Brainstorm Cell Therapeutics’s EPS estimate is -$0.15.
How many shares outstanding does Brainstorm Cell Therapeutics have?
Brainstorm Cell Therapeutics has 45,015,800 shares outstanding.
What happened to Brainstorm Cell Therapeutics’s price movement after its last earnings report?
Brainstorm Cell Therapeutics reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.145. Following the earnings report the stock price went up 3.086%.
Which hedge fund is a major shareholder of Brainstorm Cell Therapeutics?
Currently, no hedge funds are holding shares in BCLI
---
Brainstorm Cell Therapeutics Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Insider Transactions
Bought Shares
Worth $20.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 7.6%
Last 30 Days ▲ 7.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-94.64%
12-Months-Change
Fundamentals
Return on Equity
-1121.89%
Trailing 12-Months
Asset Growth
-69.69%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis and spinal cord injury. The company was founded on September 22, 2000 and is headquartered in New York, NJ.
---
Top 5 ETFs holding BCLI
Vanguard Total Stock Market ETF
$190.37K
Up to five ETFs with an Outperform Smart Score that hold BCLI. The ETFs are listed according to market value of BCLI within the ETF
---